| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Acyclovir alaninate is a prodrug that is converted to acyclovir by enzymatic hydrolysis. Acyclovir is a nucleoside analog that targets viral DNA polymerase. After conversion to acyclovir, the compound is phosphorylated by viral thymidine kinase and then by cellular kinases to acyclovir triphosphate, which inhibits viral DNA polymerase and terminates DNA chain elongation.
|
|---|---|
| ln Vitro |
Acyclovir alaninate is not directly active as an antiviral agent. Its activity is dependent on conversion to acyclovir. In vitro, acyclovir alaninate shows antiviral activity against herpes simplex virus (HSV) and varicella-zoster virus (VZV) only after hydrolysis to acyclovir. The prodrug is designed to improve oral bioavailability. Detailed in vitro antiviral data for acyclovir alaninate are limited.
|
| ln Vivo |
Acyclovir alaninate is a prodrug designed to improve the oral bioavailability of acyclovir. After oral administration, it is hydrolyzed to acyclovir, which then exerts its antiviral effects. The prodrug approach has been used to enhance the absorption and bioavailability of acyclovir. Detailed in vivo pharmacokinetic data for acyclovir alaninate are available in the pharmaceutical literature.
|
| Enzyme Assay |
In vitro antiviral assays using HSV or VZV-infected cell cultures. Cells are infected with virus and treated with acyclovir alaninate at various concentrations (typically 0.1-100 µM) for 3-7 days. Viral replication is assessed by plaque reduction assay, by measuring viral DNA by qPCR, or by measuring viral cytopathic effect. The prodrug's activity is compared to acyclovir.
|
| Cell Assay |
In vitro cell-based assays using intestinal epithelial cell lines (e.g., Caco-2) to assess the absorption and metabolism of acyclovir alaninate. Cells are treated with acyclovir alaninate, and the transport across cell monolayers is measured. The conversion of the prodrug to acyclovir is assessed by HPLC or mass spectrometry.
|
| Animal Protocol |
In vivo pharmacokinetic studies in animals or humans. Acyclovir alaninate is administered orally or intravenously at various doses. Blood and urine samples are collected at various time points. Acyclovir concentrations are measured by HPLC or immunoassay. Pharmacokinetic parameters including oral bioavailability, Cmax, Tmax, half-life, and AUC are calculated and compared to acyclovir.
|
| References |
| Molecular Formula |
C11H16N6O4
|
|---|---|
| Molecular Weight |
296.28
|
| Exact Mass |
296.123
|
| CAS # |
84499-64-9
|
| Related CAS # |
Acyclovir;59277-89-3;Acyclovir sodium;69657-51-8;Acyclovir monophosphate;66341-16-0
|
| PubChem CID |
135410330
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-1.9
|
| tPSA |
152.13
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
21
|
| Complexity |
442
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(N1C=NC2C(N=C(NC1=2)N)=O)OCCOC(=O)[C@@H](N)C
|
| InChi Key |
MUIRAGHHRGAJMO-LURJTMIESA-N
|
| InChi Code |
InChI=1S/C11H16N6O4/c1-6(12)10(19)21-3-2-20-5-17-4-14-7-8(17)15-11(13)16-9(7)18/h4,6H,2-3,5,12H2,1H3,(H3,13,15,16,18)/t6-/m0/s1
|
| Chemical Name |
2-((2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy)ethyl L-alaninate
|
| Synonyms |
Acyclovir alaninate acyclovir alaninated- [USP]Valacyclovir hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3752 mL | 16.8759 mL | 33.7519 mL | |
| 5 mM | 0.6750 mL | 3.3752 mL | 6.7504 mL | |
| 10 mM | 0.3375 mL | 1.6876 mL | 3.3752 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|